Rapamycin Pharmacokinetic and Pharmacodynamic Relationships in Osteosarcoma: A Comparative Oncology Study in Dogs
Melissa C. Paoloni, Christina Mazcko, Elizabeth Fox et al. · 2010
Read Rapamycin Pharmacokinetic and Pharmacodynamic Relationships in Osteosarcoma: A Comparative Oncology Study in Dogs by Melissa C. Paoloni, Christina Mazcko, Elizabeth Fox et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0011013.txt.
Description
Melissa Paoloni, Christina Mazcko, Elizabeth Fox and co-authors published this comparative oncology study in PLOS ONE in 2010. Rapamycin blocks the mTOR growth pathway, which drives several cancers and their resistance to chemotherapy. Instead of testing doses first in people, the team used pet dogs with naturally occurring bone cancer, a close model of the childhood disease.
Dogs with appendicular osteosarcoma entered dose cohorts of three, receiving an injected formulation while researchers tracked blood levels, safety, and whether the drug hit its target in tissue. Paoloni and colleagues sought a dose that was safe, reached relevant blood concentrations, and measurably suppressed the pathway. Using companion dogs lets pediatric oncologists skip blind dose guessing, and the dogs themselves may benefit from trials their owners choose.
Catalog record
| CREATOR | Melissa C. Paoloni, Christina Mazcko, Elizabeth Fox et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| LICENSE | Creative Commons CC0 License |
| RIGHTS | CC0 |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0011013